Related Experiment Video
Updated: Jun 6, 2026
14:45
Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
Published on: September 16, 2012
Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors
Sara Mariucci1, Bianca Rovati, Mariangela Manzoni
1S.C. Oncologia Medica, Laboratorio di Citofluorimetria e Terapie Cellulari, Fondazione IRCCS Policlinico San Matteo e Università di Pavia, Viale Golgi, Italy. flow.cytometry@smatteo.pv.it
Clinical and Experimental Medicine
|December 17, 2010
Summary
Cancer therapies like chemotherapy can weaken the immune system by depleting T-cells. Antiangiogenic drugs combined with chemotherapy may offer additional anti-tumor benefits by modulating immune responses.
Area of Science:
- Oncology
- Immunology
Background:
- Cancer patients often present with immunosuppression, primarily driven by cytotoxic antineoplastic therapy.
- This immunosuppression is linked to T-cell depletion and impaired dendritic cell function, affecting both primary and secondary immune responses.
Purpose of the Study:
- To review the impact of standard antineoplastic therapy on immune deficiency in solid tumor patients.
- To examine how antiangiogenic drugs, combined with chemotherapy, influence lymphocyte and dendritic cell subsets and potential anti-tumor mechanisms.
Main Methods:
- Literature review of existing research on cancer therapy and immune function.
- Analysis of studies investigating the effects of combined chemotherapy and antiangiogenic treatments on immune cells.
Main Results:
- Standard antineoplastic therapy significantly contributes to immunosuppression in cancer patients.
- Antiangiogenic drugs, when used with chemotherapy, may modulate immune cell populations, potentially enhancing anti-tumor activity.
Conclusions:
- Understanding the immunomodulatory effects of combined therapies is crucial for optimizing cancer treatment strategies.
- Further research into the indirect immune effects of antiangiogenic drugs could reveal novel therapeutic avenues.
